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 Abstract 
  Background:   Stroke registries contribute to the conduct of clinical research and to the assess-
ment of health care quality control. Efforts to compare clinical outcomes and quality indicators 
between centers are dependent on standardized data elements, but it is unknown how stroke 
physicians define common data elements, such as hypertension or diabetes, when collecting 
data for registries at their centers.  Methods:  We conducted an internet-based survey of 91 cen-
ters affiliated with a university to assess their definitions of common data elements (CDEs) and 
compared their responses with standardized definitions, including those from the American 
College of Cardiology (ACC).   Results:   More than half (52%) of centers completed the survey. 
There was only modest agreement among respondents regarding definitions of CDEs in the 
survey and even less agreement on how the respondents’ definitions compared to ACC stan-
dards.   Conclusions:   Surveyed respondents do not agree on the definitions of CDEs, making 
comparisons between centers problematic. Standardized definitions of CDEs are needed to im-
prove data collection for patient care and clinical research.    Copyright © 2011 S. Karger AG, Basel 
      Published online: November 5, 2011 
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 Introduction 
  Stroke registries are prospectively maintained collections of patient data that are used 
for clinical research and health care quality, federal- and state-mandated programs for hos-
pital certification, and NIH-sponsored research networks. In research focused on cerebro-
vascular disease, registries soon will be used for verification of adherence to Centers for 
Medicare/Medicaid pay-for-performance indicators. Historically, registries in stroke have 
provided important data on the prevalence and severity of vascular risk factors in the stroke 
population, approaches to acute stroke treatment, complications, and outcomes. Observed 
associations among variables in stroke registries have proven useful in the design of quality 
improvement projects and prospective clinical trials. 
    In 2001, the American College of Cardiology’s (ACC) Task Force on Clinical Data Stan-
dards published ‘Key Data Elements and Definitions for Measuring the Clinical Manage-
ment and Outcomes of Patients with Acute Coronary Syndromes’   [1, 2]  . These definitions 
were proposed to provide standardization for all centers involved in the collection of clinical 
data related to cardiovascular disease and allow for effective pooling of information from 
different centers. Unfortunately, no equivalent published guidelines exist in the literature on 
cerebrovascular disease. The NINDS is in the midst of proposing a library of CDEs or ‘com-
mon data elements’ (http://www.commondataelements.ninds.nih.gov/) for use in stroke 
studies; however, while these elements include factors such as hypertension and diabetes, the 
NINDS standards currently do not offer definitions for the elements but rather only specify 
classification for these factors as ‘yes’, ‘no’ or ‘unknown’  [3, 4] . Since cardiovascular and cere-
brovascular diseases share risk factors, the ACC standards could provide specific definitions 
for use in stroke studies as well. These ACC standards can be used to assess the validity and 
reliability of registry data from stroke centers. 
    If data elements and definitions for research in cerebrovascular disease are agreed upon 
and standardized, registry level data have the potential to promote research by allowing for 
comparison and pooled analyses of both clinical trial data and multi-site observational data. 
Registries often provide important data and observations upon which clinical trials are de-
signed and clinical trials often provide the basis for clinical care decisions. Furthermore, 
without registries, it may not be possible to readily understand the prevalence of specific 
characteristics and co-morbid diseases among an otherwise captive cohort of patients. Fi-
nally, with the impending quality performance measurement initiatives such as pay-for-per-
formance, providers would benefit from registry data that are supported by a common tax-
onomy, enhancing both validity and reliability.
  The purpose of this study was to compare the current use of definitions for data elements 
among US stroke centers that have stroke registries, and compare the use of existing stroke 
registry definitions with those already established by the ACC. We hypothesized that vascu-
lar neurologists using registry data were not making use of existing definitions published in 
the cardiology and internal medicine literature.
  Materials  and  Methods 
  Study Design, Participants, and Administration 
 From September to December 2009, we conducted a cross-sectional, internet-based sur-
vey of academic vascular neurologists in the United States at university-affiliated hospitals 
using a modified Dillman’s tailored design method   [5, 6]  . The survey was designed and con-
ducted at www.surveymonkey.com   [7]   and used our previously published methods for ob-
taining a complete list of US academic vascular neurologists   [8]  . Vascular neurologists were 86
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targeted, as they are typically the primary investigators of registry-based clinical research, 
and as such are responsible for supervising the research process, assuring study personnel 
are appropriately trained, and that they adhere to the study protocol. After an exhaustive ef-
fort to identify all stroke centers affiliated with a university in the United States, surveys were 
distributed to a total of 144 vascular neurologists. Seven of the 144 individuals had e-mail 
addresses that were nonfunctional and the correct address could not be found. This yielded 
a total sample number of 137 initial e-mails that were successfully sent to the target popula-
tion at 91 universities. 
  After     -testing by three of the authors (K.C.A., S.M.-S., and S.I.S.) and two additional 
volunteers, the survey was formally released. Participants received a pre-survey cover letter 
explaining the objectives of the study and its importance. A request to participate in the 
study, with detailed instructions, followed which provided a link to the electronic survey. 
Non-responders were sent four reminders. No incentives were provided. This study was co-
ordinated by the Vascular Neurology Program at the University of Texas School of Medicine 
in Houston. 
  Survey  Content 
  The survey consisted of 3 general questions and 10 multi-part definition questions. All 
survey questions as they were presented to respondents are shown in the online supplemen-
tary material (www.karger.com/doi/10.1159/000334146). Respondents were asked to indicate 
(1) if their institution had an active stroke registry, (2) who abstracted data at their site, and 
(3) if their site made use of a registry codebook or data dictionary. The survey focused on 10 
variables (i.e., data elements) commonly collected in stroke registries, many of which are 
specifically defined in the ACC standards: hypertension, diabetes, hyperlipidemia/dyslipid-
emia, atrial fibrillation, tobacco use, myocardial infarction, coronary artery disease, conges-
tive heart failure, carotid disease, and peripheral vascular disease   [1, 2, 9–11]  . After an ex-
haustive search of available guidelines failed to reveal a formal definition of ‘carotid disease’, 
potential definitions were generated. Participants were provided choices and instructed to 
indicate if their center currently uses each provided choice as part of their definition for each 
variable (yes or no). Respondents were then instructed to indicate if they found each of the 
provided choices ‘acceptable’ as part of their definition for each variable (yes or no). Risk fac-
tor data elements included (but did not explicitly identify) criteria listed in definitions previ-
ously published by the ACC and American Diabetes Association (ADA)   [1, 2, 11, 12]  .
    Data Collection and Analysis 
  All data was entered electronically by the participants. Analysis was performed using 
SPSS version 15.0 (SPSS Inc., Chicago, Ill., USA). The anticipated response rate was estimat-
ed at 50% (95% CI 37–63%, adjusted Wald method) based on prior studies   [12–14]  .
  R e s u l t s  
 Sample 
  Participants completed 55 self-administered surveys, representing 47 universities. Vas-
cular neurologists reported that registry data were abstracted by trained abstractors (29%), 
medical assistants (4%), nurses (29%), physician assistants (2%), fellows (2%), attending phy-
sicians (6%), or a combination of medical professionals (29%). The response rate for indi-
viduals was 40.1% (55/137) compared to 51.6% (47/91) for universities. There was no signifi-
cant difference in response rates based on Census Bureau regions (Northeast 25.5%, Midwest 
29.1%, South 27.3%, and West 18.2%, p = 0.700). 87
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  D a t a   E l e m e n t s  
  The majority of respondents (80%, 44/55) reported using a stroke registry; however, 
only 46% of respondents using a registry reported using a data dictionary to standardize 
definitions within their center.   Table 1   illustrates reported current use of examined defini-
tion criteria for 10 data elements. Patient or family report of having a data element was the 
most commonly used definition criterion, ranging from 55.8% for hyperlipidemia to 74.4% 
for hypertension and carotid endarterectomy as a surrogate for carotid disease. Current use 
of prior documentation of a condition ranged from 53.5% for tobacco use within the last 
year to 72.1% for hypertension. Current use of definition criteria related to patient medica-
tion ranged from 7.0% for peripheral vascular disease to 65.1% for diabetes. The use of lab-
oratory findings to define data elements ranged from 11.6% in ‘high-density lipoprotein  ! 40 
mg/dl’ to 44.2% in ‘glycosylated hemoglobin (HbA  1c )’ for diabetes. Use of data elements de-
rived from prior diagnostic studies ranged from 11.6% for ‘left ventricular hypertrophy on 
admission electrocardiogram (ECG)’ for hypertension to 76.7% for demonstration of atrial 
fibrillation on admission ECG. Also depicted in  table 1  is the reported acceptability for each 
data element. There was poor concordance between current use and acceptability of most 
of the definition choices, especially for the many choices offered for the data elements hy-
pertension, diabetes, and carotid disease. For the most commonly used definition criteria 
of each of the 10 data elements, at least 20% fewer respondents found definition criteria to 
be acceptable.
  Discussion 
  The majority of centers surveyed are actively collecting stroke registry data on key ele-
ments such as hypertension or diabetes. However, few centers appear to have formal guide-
lines in place (e.g., codebook/data dictionary) to assist them with the within-site standard-
ization of definitions for these variables. No more than three fourths of respondents were 
using or found any provided definition criteria to be acceptable for any of the data elements. 
For each data element, far more respondents were using a stated history of the data element 
to define its presence, than those that actually found a stated history to be an acceptable 
criterion. Researchers using and combining registry data may not agree on the definitions 
or even know the definitions used in the acquisition of the data they house in their regis-
tries. 
    The results of this survey suggest there is little consensus among US centers regarding 
the actual definition of CDEs in cardiovascular and cerebrovascular diseases. The preva-
lence of these data elements and association of these data elements with other patient char-
acteristics or outcomes will be substantially affected by the definitions applied, making the 
interpretation of results from these registries problematic. There are various possible reasons 
for the lack of consensus. There may be a lack of agreement about the purpose of the registry, 
i.e., what question or questions it will answer, or a belief that a registry can be created that 
will be able to answer a wide variety of questions without compromising quality. Without a 
prospective and limited list of questions to answer, one can understand why it is hard to agree 
on how data fields are defined.
  In addition, our study found that vascular neurologists are not currently using published 
ACC or ADA definition criteria for data elements. It is possible that stroke neurologists are 
not familiar with the ACC guidelines; however, our survey found that they often do not agree 
with the data element definitions proposed by the ACC. 
    The evolving acceptance of definitions by specialty organizations (e.g., ACC or ADA) is 
one barrier to the adoption of definitions for stroke registries. For example, in 2010 the ADA 88
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Table 1.   Current use and acceptability of definition criteria for 10 stroke registry data elements
Current use
(n = 43)
Also accept-
a  ble (n = 46)
%  (n) %  (n)
Hypertension (HTN)
1 Patient or family states that s/he has a history of diagnosed HTN 74.4 (32) 47.8 (22)
2 Prior documentation of HTN 72.1 (31) 47.8 (22)
3 Admission ECG reads left ventricular hypertrophy (LVH) 11.6 (5) 43.5 (20)
4 Prior echo shows concentric LVH 14.0 (6) 37.0 (17)
5 Patient is currently on any antihypertensive medication (e.g., ACE inhibitors, angiotensin receptor  55.8 (24) 30.4 (14)
blockers, -blockers, thiazide diuretics, calcium channel blockers) for no other known reason (e.g., 
systolic heart failure, rate control of atrial fibrillation, migraine prevention)
6 Other 2.3 (1) 4.3 (2)
7 We do not have a formal definition 25.6 (11) 4.3 (2)
Diabetes mellitus (DM)
1 Patient or family states that s/he has a history of diagnosed diabetes 69.8 (30) 41.3 (19)
2 Prior admission notes, discharge summaries or clinic notes list DM  72.1 (31) 41.3 (19)
3 Existing medical records show a random plasma glucose concentration ≥200 mg/dl in association with  34.9 (15) 47.8 (22)
polyuria, polydipsia, or unexplained weight loss1
4 Existing medical records show a fasting (i.e., no caloric intake for at least 8 h) plasma glucose value 27.9 (12) 47.8 (22)
≥126 mg/dl (in an asymptomatic patient)1
5 Existing medical records show a 2-hour plasma glucose value ≥200 mg/dl during an oral glucose tolerance  27.9 (12) 56.5 (26)
test (in an asymptomatic patient)1
6 Admission or previous HbA1c ≥7.01 44.2 (19) 37.0 (17)
7 Patient is currently on any of the following medications: metformin, glyburide, pioglitazone,  65.1 (28) 43.5 (20)
rosiglitazone, glipizide/Glucotrol, any form of insulin (e.g., Humalog, Humulin, Lantus, Novolin, 
NovoLog, 70/30)
8 Other 0 (0) 2.2 (1)
9 We do not have a formal definition 23.3 (10) 4.3 (2)
Hyperlipidemia (HLP) or dyslipidemia
1 Patient or family states that s/he has a history of diagnosed HLP 55.8 (24) 34.8 (16)
2 Patient or family states that s/he has a history of diagnosed dyslipidemia [i.e., elevated triglycerides,  58.1 (25) 34.8 (16)
low high-density lipoprotein (HDL)]
3 Prior documentation of HLP 65.1 (28) 37.0 (17)
4 Prior documentation of dyslipidemia 55.8 (24) 32.6 (15)
5 Admission or previous total cholesterol >200 mg/dl (5.18 mmol/l) 25.6 (11) 32.6 (15)
6 Admission or previous low-density lipoprotein (LDL) ≥130 mg/dl (3.37 mmol/l) 34.9 (15) 47.8 (22)
7 Admission or previous LDL is >100 mg/dl (2.59 mmol/l) in patients with known coronary artery  30.2 (13) 30.4 (14)
disease or stroke
8 Admission or previous HDL <40 mg/dl (1.04 mmol/l) 11.6 (5) 28.3 (13)
9 Patient is currently on any of the following medications: statin/HMG-CoA reductase inhibitors,  51.2 (22) 37.0 (17)
fibrates, nicotinic acid, resin drugs (e.g., atorvastatin, simvastatin, pravastatin, fluvastatin, 
lovastatin, cholestyramine, colestipol, probucol, gemfibrozil, Niaspan)
10 Other 2.3 (1) 2.2 (1)
11 We do not have a formal definition 23.3 (10) 4.3 (2)
Atrial fibrillation (AF)
1 Patient or family states that s/he has history of AF 62.8 (27) 39.1 (18)
2 Prior documentation of AF 74.4 (32) 39.1 (18)
3 Admission ECG shows AF 76.7 (33) 39.1 (18)
4 Admission ECG shows atrial flutter  39.5 (17) 30.4 (14)
5 Prior echo shows AF/atrial flutter 25.6 (11) 23.9 (11)
6 Prior Holter monitoring or event recording revealed AF 62.8 (27) 43.5 (20)
7 Prior Holter monitoring or event recording revealed atrial flutter 39.5 (17) 32.6 (15)
8 Patient reports a history of ‘irregular heartbeats’ without knowledge of term AF 2.3 (1) 2.2 (1)
9 Other 0 (0) 2.2 (1)
10 We do not have a formal definition 16.3 (7) 2.2 (1)89
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Table 1 (continued)
Current use
(n = 43)
Also accept-
a  ble (n = 46)
%  (n) %  (n)
Tobacco use 
1 Patient or family states that s/he currently uses tobacco (cigars, cigarettes, smokeless tobacco) 72.1 (31) 41.3 (19)
2 Patient or family states that s/he has used tobacco in the last year (cigars, cigarettes, smokeless tobacco) 67.4 (29) 37.0 (17)
3 Prior documentation of tobacco use in the last year 53.5 (23) 37.0 (17)
4 Other 0 (0) 2.2 (1)
5 We do not have a formal definition 16.3 (7) 2.2 (1)
Myocardial infarction (MI)
1 Patient or family states that s/he has a history of MI 62.8 (27) 34.8 (16)
2 Prior documentation of MI 67.4 (29) 34.8 (16)
3 Admission ECG shows ST-segment elevation in a lead group 25.6 (11) 23.9 (11)
4 Admission ECG shows either ST-segment depression or T-wave abnormalities – in the absence of ST  20.9 (9) 21.7 (10)
elevation in a lead group
5 Q waves present on admission ECG in a lead group  27.9 (12) 32.6 (15)
6 History of MI symptoms in the presence or absence of chest discomfort; ischemic symptoms may include:  9.3 (4) 10.9 (5)
unexplained nausea and vomiting or diaphoresis, persistent shortness of breath secondary to left ventricular
failure, unexplained weakness, dizziness, lightheadedness, or syncope
7 Prior echo shows evidence of regional wall motion abnormalities consistent with prior MI 27.9 (12) 28.3 (13)
8 Prior nuclear imaging studies, exercise radionuclide ventriculography or pharmacologic stress  25.6 (11) 32.6 (15)
echocardiography consistent with prior MI
9 Other 0 (0) 2.2 (1)
10 We do not have a formal definition 23.3 (10) 2.2 (1)
Coronary artery disease (CAD)
1 Patient or family states that s/he has history of prior coronary artery bypass graft (CABG) or percutaneous 69.8 (30) 39.1 (18)
transluminal coronary angioplasty (PTCA)/percutaneous coronary intervention (PCI)
2 Prior documentation of CABG or PTCA/PCI including balloon angioplasty, atherectomy, stent, or other 67.4 (29) 37.0 (17)
3 Wires seen on chest X-ray without alternate explanation 18.6 (8) 17.4 (8)
4 Scar on chest or scar on leg from vein harvest 11.6 (5) 17.4 (8)
5 Has current prescription for long-acting nitrates (isosorbide mononitrate or dinitrate) 23.3 (10) 15.2 (7)
6 Has current prescription for sublingual nitroglycerin 27.9 (12) 19.6 (9)
7 Other 0 (0) 2.2 (1)
8 We do not have a formal definition 23.3 (10) 4.3 (2)
Congestive heart failure (CHF)
1 Patient or family states that s/he has a history of CHF 58.1 (25) 30.4 (14)
2 Prior documentation of CHF 62.8 (27) 34.8 (16)
3 Prior echocardiogram demonstrated reduced left ventricular ejection fraction (<50%) 25.6 (11) 21.7 (10)
4 History or current symptoms of dyspnea, orthopnea, and fluid retention 30.2 (13) 13.0 (6)
5 Examination demonstrates crackles, rales, or jugular venous distension 20.9 (9) 19.6 (9)
6 Admission chest X-ray demonstrates pulmonary edema with pulmonary venous congestion and  25.6 (11) 28.3 (13)
cephalization of vasculature
7 Markedly elevated brain natriuretic peptide on current admission or any prior assessment  23.3 (10) 23.9 (11)
8 On combination regimen(s) suggestive of heart failure (e.g., ACE inhibitors + loop diuretic,  11.6 (5) 15.2 (7)
hydralazine + nitrate)
9 Patients instructed to weigh themselves daily 2.3 (1) 6.5 (3)
10 Other 2.3 (1) 4.3 (2)
11 We do not have a formal definition 23.3 (10) 4.3 (2)
Carotid disease
1 Patient or family states that s/he has history of carotid disease 58.1 (25) 23.8 (13)
2 Patient or family states that s/he has history of carotid stenting 72.1 (31) 32.6 (15)
3 Patient or family states that s/he has history of carotid endarterectomy (CEA) 74.4 (32) 39.1 (18)
4 Prior documentation of carotid disease  72.1 (31) 34.8 (16)
5 Prior documentation of carotid stenting 72.1 (31) 37.0 (17)
6 Prior documentation of CEA 74.4 (32) 37.0 (17)
7 Evidence of >50% stenosis of an extracranial carotid artery on imaging (e.g., ultrasound, MRA, CTA,  60.5 (26) 34.8 (16)
angiogram)
8 CEA scar 32.6 (14) 30.4 (14)
9 Evidence of carotid stent or CEA on imaging 46.5 (20) 37.0 (17)
10 Other 0 (0) 2.2 (1)
11 We do not have a formal definition 18.6 (8) 2.2 (1)90
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approved the use of HbA  1c   measurement of   6  6.5% to meet the criteria for diabetes mellitus. 
If stroke registries uniformly incorporate this criterion, the prevalence of diabetes mellitus 
may increase from rates previously demonstrated. If the criterion is not uniformly incorpo-
rated, data regarding diabetes mellitus cannot be compared nor combined from center to 
center. As other methods of diagnosing stroke risk factors are proposed and validated, cen-
ters using registries need to have a plan for how to adapt and incorporate new criteria. Sim-
ilar to the standardized definitions that support evidence-based process measures endorsed 
by the National Quality Forum for adoption by the Centers for Medicare/Medicaid Services, 
definitions for medical diagnoses or the presence/absence of symptoms or disease character-
istics are essential. Without this standardization, the validity of findings from the best pro-
cess measures is ultimately threatened due to measurement error.
    Our study has a number of limitations. First, the generalizability of this study is limited 
by its 40.1% response rate; however, our response rate is in keeping with a review of 31 e-mail 
surveys that reported a mean response rate of 36.8% and recent stroke surveys assessing opin-
ions of university-affiliated stroke neurologists  [8, 12–14] . While self-administered web-based 
surveys have been shown to result in lower response rates and more missing data, they do have 
the advantage of diminishing social desirability bias and response order effects. Secondly, de-
spite our efforts to     -test survey questions prior to disseminating the survey, we cannot be 
certain that the responses regarding currently used and acceptable definitions of CDEs ac-
curately represent the opinions of other neurologists within the same stroke center. For ex-
ample, respondents at centers that use a prespecified protocol with standardized definitions 
to perform retrospective chart abstraction may have indicated that they did not currently use 
a registry codebook or a data dictionary, despite using standardized definitions. Further, we 
cannot disregard the potential influence of close-ended, leading, or loaded questions on re-
spondents, despite our efforts to avoid double-barrel questions by separating the ‘current use’ 
and ‘also acceptable’ answer choices. It is possible that our target population did not represent 
all hospitals collecting registry level data, as many hospitals not affiliated with universities 
may also collect data to support their programs of research as well as stroke center certifica-
tion. Lastly, we wish to point out that the results of this study should not be misconstrued to 
equate registries with well-designed epidemiological studies and controlled clinical trials.
Current use
(n = 43)
Also accept-
a  ble (n = 46)
%  (n) %  (n)
Peripheral vascular disease (PVD)
1 Patient or family states that s/he has a history of PVD 58.1 (25) 28.3 (13)
2 Prior documentation of PVD 58.1 (25) 32.6 (15)
3 History of claudication, either with exertion or at rest 41.9 (18) 34.8 (16)
4 History of amputation for arterial vascular insufficiency 48.8 (21) 37.0 (17)
5 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities 48.8 (21) 39.1 (18)
6 Documented aortic aneurysm 16.3 (7) 21.7 (10)
7 Positive noninvasive test (e.g., ankle brachial index <0.8) or lower extremity US with arterial Doppler 37.2 (16) 43.5 (20)
8 Absence of peripheral pulses on examination 20.9 (9) 26.1 (12)
9 On medication, e.g., Pletal/cilostazol 7 (3) 13.0 (6)
10 PVD demonstrated on imaging (e.g., angiography) 39.5 (17) 37.0 (17)
11 Other 0 (0) 2.2 (1)
12 We do not have a formal definition 32.6 (14) 2.2 (1)
Dat  a elements derived from ACC Guidelines are in bold [1, 2]. 
1 Data elements derived from ADA.
Table 1 (continued)91
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  To the best of our knowledge, this is the first study to provide quantitative evidence sup-
porting the NINDS proposal for creating a library of CDEs. The implications of our findings 
are practical, as existing inconsistencies in definitions may substantially impair our ability 
to detect associations between variables, limit the ability to generalize the observational data 
of a single center, and confound multi-site collaboration. Given the concerted efforts by aca-
demic institutions to collect data for clinical research, standardization of data elements is of 
paramount importance. This study supports the argument that consensus guidelines need 
to be developed to outline and define key data elements, to optimize and standardize data 
collection for the purpose of clinical research.
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